HCA Healthcare, Inc. $HCA Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. decreased its holdings in shares of HCA Healthcare, Inc. (NYSE:HCA) by 1.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 425,288 shares of the company’s stock after selling 7,853 shares during the period. Sumitomo Mitsui Trust Group Inc. owned approximately 0.18% of HCA Healthcare worth $181,258,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Norges Bank purchased a new position in HCA Healthcare during the 2nd quarter worth $1,152,408,000. Viking Global Investors LP boosted its holdings in HCA Healthcare by 58.5% in the 2nd quarter. Viking Global Investors LP now owns 1,872,133 shares of the company’s stock valued at $717,214,000 after purchasing an additional 690,773 shares in the last quarter. Nordea Investment Management AB lifted its holdings in shares of HCA Healthcare by 6.8% in the 2nd quarter. Nordea Investment Management AB now owns 927,781 shares of the company’s stock valued at $350,404,000 after buying an additional 59,163 shares during the period. Pacer Advisors Inc. boosted its position in shares of HCA Healthcare by 6,115.3% during the 3rd quarter. Pacer Advisors Inc. now owns 911,096 shares of the company’s stock worth $388,309,000 after purchasing an additional 896,437 shares in the last quarter. Finally, LSV Asset Management lifted its stake in shares of HCA Healthcare by 0.4% in the second quarter. LSV Asset Management now owns 868,849 shares of the company’s stock valued at $332,856,000 after purchasing an additional 3,396 shares during the period. Institutional investors and hedge funds own 62.73% of the company’s stock.

HCA Healthcare Stock Up 0.5%

NYSE:HCA opened at $474.23 on Tuesday. The company has a market cap of $108.21 billion, a P/E ratio of 18.33, a P/E/G ratio of 1.30 and a beta of 1.36. The firm’s 50 day moving average is $480.14 and its two-hundred day moving average is $428.44. HCA Healthcare, Inc. has a fifty-two week low of $295.00 and a fifty-two week high of $520.00.

HCA Healthcare (NYSE:HCA) last issued its earnings results on Friday, October 24th. The company reported $6.96 earnings per share for the quarter, topping the consensus estimate of $5.64 by $1.32. The business had revenue of $19.16 billion for the quarter, compared to analyst estimates of $18.55 billion. HCA Healthcare had a negative return on equity of 792.25% and a net margin of 8.53%.The business’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period last year, the company posted $4.90 EPS. HCA Healthcare has set its FY 2025 guidance at 27.000-28.000 EPS. Research analysts forecast that HCA Healthcare, Inc. will post 24.98 earnings per share for the current fiscal year.

HCA Healthcare Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 29th. Shareholders of record on Monday, December 15th were paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 0.6%. The ex-dividend date was Monday, December 15th. HCA Healthcare’s payout ratio is currently 11.13%.

Insiders Place Their Bets

In related news, EVP Michael R. Mcalevey sold 3,892 shares of the stock in a transaction on Wednesday, November 5th. The stock was sold at an average price of $473.79, for a total value of $1,843,990.68. Following the completion of the sale, the executive vice president directly owned 3,487 shares in the company, valued at approximately $1,652,105.73. This represents a 52.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.30% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on HCA. Truist Financial boosted their target price on HCA Healthcare from $495.00 to $520.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. Zacks Research lowered HCA Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 27th. Wall Street Zen raised shares of HCA Healthcare from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 25th. Robert W. Baird boosted their price objective on shares of HCA Healthcare from $423.00 to $450.00 and gave the company a “neutral” rating in a research report on Thursday, December 11th. Finally, UBS Group boosted their price target on HCA Healthcare from $495.00 to $525.00 and gave the company a “buy” rating in a report on Monday, October 27th. Fourteen investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $485.95.

HCA Healthcare Profile

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.